Metformin 750 mg Extended Release Recalled for NDMA Contamination
RemedyRepack Inc. is recalling Metformin 750 mg Extended Release (NDC # 70518-2920-00) due to detection of N-Nitrosodimethylamine (NDMA) levels exceeding the acceptable daily intake limit. The product was distributed to one direct account in Pennsylvania.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall involving a contaminant (NDMA) detected above acceptable levels. The source text does not report any illnesses, hospitalizations, or injuries. The recall addresses a manufacturing/quality deviation rather than a known safety incident, which aligns with Moderate severity for a precautionary Class II recall.
Plain-English summary
RemedyRepack Inc. is recalling Metformin 750 mg Extended Release tablets (NDC # 70518-2920-00) in 56 blister cards. The recall was issued due to CGMP deviations and the detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.
The affected product includes the following lot numbers and expiration dates: Lot # J0511265-021121 (exp. 02/28/2022), Lot # J0499451-122220 (exp. 01/31/2022), Lot # J0496563-120820 (exp. 12/31/2021), and Lot # J0495111-120120 (exp. 12/31/2021). The product was distributed to one direct account in Pennsylvania.
Consumers who have this medication should stop taking it and contact their healthcare provider or pharmacist for guidance. Healthcare providers should advise patients to return the recalled product.
The recalled product
- Product
- Metformin 750 mg Extended Release NDC # 70518-2920-00
- Manufacturer
- RemedyRepack Inc.
- Category
- Drug — Antidiabetic
- Affected units
- 56
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (5)
- Lot # J0511265-021121
- exp. date 02/28/2022 J0499451-122220
- exp. date 01/31/2022 J0496563-120820
- exp. date 12/31/2021 J0495111-120120
- exp. date 12/31/2021
Distribution
Distributed in 1 state:
Related recalls
Same manufacturer · RemedyRepack Inc.
See all →- ModerateClindamycin HCl Capsule 300 mg repackaged by RemedyRePack Inc.
FDA (Drugs) · 2025-05-14
- ModerateClindamycin HCl 300 mg Capsule Recalled for CGMP Deviations
FDA (Drugs) · 2025-04-30
- HighCarvedilol 25 mg tablets recalled due to N-nitroso impurity above limit
FDA (Drugs) · 2025-02-12
- HighDuloxetine delayed-release capsules recalled due to manufacturing impurity
FDA (Drugs) · 2025-01-01
- HighPotassium Chloride Extended Release Capsules Recalled for Dissolution Defect
FDA (Drugs) · 2024-07-24
Same hazard · ndma contamination
See all →- SevereMetformin Hydrochloride Extended-Release Tablets Recalled for NDMA Contamination
FDA (Drugs) · 2022-02-02
- HighMetformin Hydrochloride Tablets Recalled for NDMA Contamination
FDA (Drugs) · 2021-06-30
- SeverePreferred Pharmaceuticals Recalls Metformin HCl Extended Release Tablets Due to NDMA
FDA (Drugs) · 2020-11-25
- SeverePreferred Pharmaceuticals Recalls Metformin HCl Extended Release Tablets Due to NDMA
FDA (Drugs) · 2020-07-08
- SevereAmneal Recalls Nizatidine Oral Solution Due to Potential NDMA Contamination
FDA (Drugs) · 2020-05-06